Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNJ013
MIFTS: 65

Conjunctivitis

Categories: Eye diseases, Immune diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Conjunctivitis

About this section

MalaCards integrated aliases for Conjunctivitis:

Name: Conjunctivitis 12 77 30 56 45 15 17 74 3 64
Madras Eye 12

Classifications:

MalaCards categories:
Anatomical: Eye diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:6195
ICD9CM 36 372.30
MeSH 45 D003231
NCIt 51 C34504
SNOMED-CT 69 9826008
ICD10 34 H10 H10.9
UMLS 74 C0009763
Sources

Summaries for Conjunctivitis

About this section
PubMed Health : 64 About conjunctivitis: Conjunctivitis, also known as pink eye, is an inflammation of the conjunctiva. The conjunctiva is a protective membrane covering the white part of the eye and the inner side of the eyelid. When people have conjunctivitis, both of their eyes are often red because the infection can spread very easily from one eye to the other.Conjunctivitis is most commonly caused by bacteria or viruses, and sometimes by an allergy. Bacterial conjunctivitis usually gets better within a week without treatment, but viral infections can last as long as four weeks.Because the virus can easily spread through contact with your fingers, it is important not to touch an infected eye with your bare hands. If you do touch your eye, be sure to wash your hands right away. It is also a good idea to use your own towels and washcloths, and not share them with other people.

MalaCards based summary : Conjunctivitis, also known as madras eye, is related to giant papillary conjunctivitis and papillary conjunctivitis, and has symptoms including bloodshot eye, conjunctival congestion and redness of eye. An important gene associated with Conjunctivitis is PLG (Plasminogen), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Oralair and Bepotastine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and skin, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A conjunctival disease characterized by an inflammation of the conjunctiva, the outermost layer of the eye and the inner surface of the eyelids.

CDC : 3 People often call conjunctivitis “pink eye” because it can cause the white of the eye to take on a pink or red color. Symptoms of pink eye can vary but typically include redness or swelling of the white of the eye.

Wikipedia : 77 Conjunctivitis, also known as pink eye, is inflammation of the outermost layer of the white part of the... more...

Sources

Related Diseases for Conjunctivitis

About this section

Diseases in the Conjunctivitis family:

Acute Conjunctivitis Chronic Conjunctivitis
Bacterial Conjunctivitis

Diseases related to Conjunctivitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 829)
# Related Disease Score Top Affiliating Genes
1 giant papillary conjunctivitis 33.9 CCL11 CXCL8 IL4 RNASE3
2 papillary conjunctivitis 33.4 CCL11 CXCL8 IL4 IL6
3 chronic conjunctivitis 33.1 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
4 blepharoconjunctivitis 32.9 CCL11 IL4 RNASE3
5 allergic conjunctivitis 32.4 CCL11 CXCL8 HRH1 ICAM1 IFNG IL13
6 vernal conjunctivitis 32.4 EPX IFNG IL2 IL4 MS4A2 RNASE3
7 measles 31.9 IFNG IL2 IL4 IL6
8 stevens-johnson syndrome/toxic epidermal necrolysis 31.1 IFNG IL13 IL2 IL5
9 chlamydia 30.7 CXCL8 IFNG IL4 IL6
10 pollen allergy 30.6 EPX FOXP3 ICAM1 IL13 IL5 RNASE3
11 uveitis 30.4 ICAM1 IFNG IL4
12 dermatitis 30.1 CCL11 IFNG IL13 IL4 IL5
13 scleritis 30.0 IFNG IL4 IL5
14 viral infectious disease 30.0 CXCL8 IFNG IL2 IL4 IL6
15 lichen planus 30.0 ICAM1 IFNG IL4
16 myasthenia gravis 29.9 IFNG IL2 IL4
17 variola major 29.9 IFNG IL2
18 meningitis 29.9 CXCL8 IFNG IL6 NLRP3
19 graves' disease 29.9 ICAM1 IFNG IL4
20 urticaria 29.8 HRH1 NLRP3 RNASE3
21 graft-versus-host disease 29.8 IFNG IL2 IL6
22 coccidiosis 29.8 IFNG IL2 IL4
23 respiratory syncytial virus infectious disease 29.8 IL13 IL5
24 otitis media 29.8 CCL11 CXCL8 IL4 IL6 RNASE3
25 sinusitis 29.7 CXCL8 IL5 RNASE3
26 periodontitis 29.7 CXCL8 IFNG IL4 IL6
27 sarcoidosis 1 29.6 IFNG IL13 IL2
28 hematopoietic stem cell transplantation 29.6 IFNG IL2 IL6
29 spondyloarthropathy 29.6 IFNG IL4 IL6
30 bullous pemphigoid 29.6 CCL11 IL5 RNASE3
31 vernal keratoconjunctivitis 29.6 CCL11 ICAM1 IL13 IL4 IL5 RNASE3
32 synovitis 29.6 CXCL8 ICAM1 IL6
33 poliomyelitis 29.5 ICAM1 IFNG IL4
34 osteomyelitis 29.5 CXCL8 IFNG IL6
35 necrotizing fasciitis 29.5 CXCL8 IL2 IL6
36 lymphopenia 29.5 FOXP3 IFNG IL2
37 erythema multiforme 29.5 ICAM1 IFNG IL2
38 pancreas adenocarcinoma 29.4 FOXP3 IFNG MUC16
39 allergic contact dermatitis 29.4 CXCL8 ICAM1 IFNG IL4 IL5
40 allergic rhinitis 29.3 CCL11 CXCL8 EPX HRH1 ICAM1 IFNG
41 aspergillosis 29.3 IFNG IL4 IL5
42 gingivitis 29.3 CXCL8 IL4 IL6
43 yellow fever 29.2 IL4 IL5 IL6
44 contact dermatitis 29.2 CXCL8 ICAM1 IFNG IL4 IL5 IL6
45 interstitial lung disease 29.2 CXCL8 IFNG IL4 IL6
46 aggressive periodontitis 29.1 CXCL8 IL4 IL6
47 ulcerative colitis 29.1 CXCL8 IFNG IL2 IL6
48 pneumonia 29.1 CCL11 CXCL8 IL13 IL5 IL6
49 tonsillitis 29.0 CXCL8 IFNG IL2 IL4 IL6
50 keratoconjunctivitis 29.0 CCL11 CXCL8 ICAM1 IFNG IL13 IL2

Comorbidity relations with Conjunctivitis via Phenotypic Disease Network (PDN): (show all 21)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Blepharitis
Bronchitis Chronic Myocardial Ischemia
Decubitus Ulcer Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Ischemic Heart Disease
Osteoporosis Parkinson Disease, Late-Onset
Protein-Energy Malnutrition Respiratory Failure
Schizophreniform Disorder Swallowing Disorders
Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Conjunctivitis:



Diseases related to Conjunctivitis
Sources

Symptoms & Phenotypes for Conjunctivitis

About this section

UMLS symptoms related to Conjunctivitis:


bloodshot eye, conjunctival congestion, redness of eye, discharge from eye

MGI Mouse Phenotypes related to Conjunctivitis:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 CCL11 EPX FOXP3 HRH1 ICAM1 IFNG
2 immune system MP:0005387 10.25 CCL11 EPX FOXP3 HRH1 ICAM1 IFNG
3 growth/size/body region MP:0005378 10.22 FOXP3 HRH1 ICAM1 IFNG IL13 IL2
4 digestive/alimentary MP:0005381 10.21 FOXP3 ICAM1 IFNG IL13 IL2 IL4
5 homeostasis/metabolism MP:0005376 10.17 FOXP3 HRH1 ICAM1 IFNG IL13 IL2
6 endocrine/exocrine gland MP:0005379 10.1 FOXP3 ICAM1 IFNG IL13 IL2 IL4
7 integument MP:0010771 9.97 FOXP3 ICAM1 IFNG IL13 IL4 IL6
8 liver/biliary system MP:0005370 9.97 FOXP3 HRH1 IFNG IL2 IL4 IL5
9 reproductive system MP:0005389 9.81 FOXP3 IFNG IL13 IL2 IL4 IL5
10 neoplasm MP:0002006 9.73 ICAM1 IFNG IL2 IL5 IL6 PLG
11 respiratory system MP:0005388 9.61 CCL11 FOXP3 IFNG IL13 IL2 IL4
12 vision/eye MP:0005391 9.17 FOXP3 ICAM1 IFNG IL2 IL4 IL6
Sources

Drugs & Therapeutics for Conjunctivitis

About this section

PubMedHealth treatment related to Conjunctivitis: 64

Eye drops or ointments that contain antibiotics are often given as a treatment for conjunctivitis just in case it is a bacterial infection, even though conjunctivitis is more commonly caused by viruses. But antibiotics are only effective against bacteria, and have no effect on viruses. If the infection is viral, only the symptoms can be treated.Some people use non-antibiotic eye drops. Cold or warm compresses are also common. The effects of these treatments have not been properly studied, though. It is not clear if they are helpful, useless or possibly even harmful.If conjunctivitis is caused by an allergy, it can be treated with allergy medicine such as antihistamines.

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Oralair 19 Greer Labs April 2014

Drugs for Conjunctivitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 399)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bepotastine Approved Phase 4,Phase 2,Phase 3 125602-71-3, 190786-44-8 2350
2
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
3
Alcaftadine Approved Phase 4,Phase 3 147084-10-4 19371515
4
Pseudoephedrine Approved Phase 4,Phase 3,Phase 2 90-82-4 7028
5
Pheniramine Approved Phase 4 86-21-5 4761
6
Naphazoline Approved, Investigational Phase 4,Phase 3 835-31-4 4436
7
Ephedrine Approved Phase 4,Phase 3,Phase 2 299-42-3 9294
8
Loteprednol Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 82034-46-6, 129260-79-3 444025 9865442
9
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2 2921-57-5
10
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
11
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2 302-25-0
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
13
Acitretin Approved Phase 4 55079-83-9, 69427-46-9 6437841
14
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2 90566-53-3 62924
15
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492 6473866
16
Tocopherol Approved, Investigational Phase 4,Not Applicable 1406-66-2 14986
17
Povidone Approved Phase 4,Phase 3,Not Applicable 9003-39-8
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
19
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
20
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1177-87-3
22
Polymyxin B Approved, Vet_approved Phase 4,Phase 3 1404-26-8
23
Ketotifen Approved Phase 4,Phase 3,Phase 1,Phase 2 34580-14-8, 34580-13-7 3827
24
Ganciclovir Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 82410-32-0 3454
25
Dipivefrin Approved Phase 4,Phase 3,Phase 2,Phase 1 52365-63-6 3105
26
Tobramycin Approved, Investigational Phase 4,Phase 3,Not Applicable 32986-56-4 5496 36294
27
Iodine Approved, Investigational Phase 4,Phase 3,Not Applicable 7553-56-2 807
28
Glycerol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-81-5 753
29
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
30
Fluorometholone Approved, Investigational Phase 4,Phase 3,Not Applicable 426-13-1 9878
31
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2 28014-46-2
32
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 50-28-2 5757
33
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2 57-63-6 5991
34
Moxifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 354812-41-2, 151096-09-2 152946
35
Norgestimate Approved, Investigational Phase 4,Phase 3,Phase 2 35189-28-7 6540478
36
Epinastine Approved, Investigational Phase 4,Phase 3 80012-43-7 3241
37
Trimethoprim Approved, Vet_approved Phase 4,Phase 3 738-70-5 5578
38
Gatifloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 112811-59-3 5379
39
Desloratadine Approved, Investigational Phase 4,Phase 3 100643-71-8 124087
40
Epinephrine Approved, Vet_approved Phase 4,Phase 3 51-43-4 5816
41
Racepinephrine Approved Phase 4,Phase 3 329-65-7 838
42
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
43
Montelukast Approved Phase 4 158966-92-8 5281040
44
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83905-01-5 55185 447043
45
Permethrin Approved, Investigational Phase 4,Phase 2 52645-53-1 40326
46
Lifitegrast Approved Phase 4,Phase 3,Phase 2,Not Applicable 1025967-78-5
47
Ketorolac Approved Phase 4,Phase 2,Phase 3 66635-83-4, 74103-06-3 3826
48
Menthol Approved Phase 4 2216-51-5 16666
49
Ethanol Approved Phase 4,Phase 2,Not Applicable 64-17-5 702
50
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379

Interventional clinical trials:

(show top 50) (show all 967)
# Name Status NCT ID Phase Drugs
1 Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses Unknown status NCT01337557 Phase 4 Bepotastine
2 Comparison of Tolerability Between Two Allergy Drops Unknown status NCT01390961 Phase 4 alacaftadine and naphazoline HCl & pheniramine maleate
3 The Effect of BEPREVE 1.5% on Tear Film Osmolarity and Tear Film Lipid Layer Unknown status NCT01346371 Phase 4 Bepreve (bepotastine ophthalmic solution) 1.5%
4 A Study to Evaluate the Safety and Efficacy of Lotemax Ophthalmic Suspension 0.5% Unknown status NCT01437982 Phase 4 Loteprednol Etabonate;Prednisolone Acetate 1% Oph Susp
5 Efficacy and Safety of LAIS® Mites Sublingual Tablets Unknown status NCT02277483 Phase 4 LAIS®
6 Ocular Allergy Treatment Practical Impact Trial Unknown status NCT01808768 Phase 4 Alcaftadine
7 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
8 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
9 Topical Tacrolimus in Vernal Keratoconjunctivitis Unknown status NCT02456025 Phase 4 Topical tacrolimus
10 Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity Unknown status NCT02992535 Phase 4
11 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
12 Efficacy of FreshKote and Systane for the Treatment of Dry Eye and Improvement of Osmolarity Unknown status NCT01386073 Phase 4 FreshKote;Systane
13 Altaire Gel Forming Solution Versus Refresh Tears for the Treatment of Dry Eye Signs and Symptoms Unknown status NCT01382810 Phase 4 Altaire Gel forming solution;Refresh Tears
14 Comparison of Efficacy, Safety and Anti-Inflammatory Effect Between Topical 0.05%Cyclosporine A Emulsion and REFRESH® in Patients With Moderate to Severe Dry Eyes Unknown status NCT00704275 Phase 4 0.05% cyclosporin eye drop
15 0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients Unknown status NCT02595606 Phase 4 0.3% Sodium Hyaluronate
16 Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus Unknown status NCT00797030 Phase 4 cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
17 Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Completed NCT01697969 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2%
18 Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis Completed NCT01119287 Phase 4 Dexamethasone 0.1% ophthalmic suspension;Olopatadine hydrochloride 0.1% ophthalmic solution
19 Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis Completed NCT01443442 Phase 4 bepotastine besilate, 1.5%;Loteprednol etabonate
20 A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis Completed NCT00655109 Phase 4 Olopatadine;Fluticasone;Saline;Artificial tears
21 Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment Completed NCT00798577 Phase 4 Vigamox Ophthalmic Solution;BSS placebo
22 Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora Completed NCT00312338 Phase 4 VIGAMOX
23 Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan Completed NCT02251613 Phase 4 Olopatadine HCl ophthalmic solution, 0.1%;Epinastine HCl ophthalmic solution, 0.05%
24 Moxifloxacin vs. Polytrim for Conjunctivitis Completed NCT00581542 Phase 4 moxifloxacin;polytrim
25 Ketotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis Completed NCT00133627 Phase 4 Ketotifen
26 A Study of Patient Perception and Quality of Life Associated With the Use of Olopatadine 0.2% in Subjects With Allergic Conjunctivitis Completed NCT01272089 Phase 4 Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
27 Evaluation of the Effect and Tolerance of Preservative Free NAAGA on the Inflammatory Component and Symptoms of Dry Eye Syndrome in Allergic Conjunctivitis Patients Completed NCT01203540 Phase 4 NAABAK eyedrops;Saline eyedrops
28 Patient Perceptions and Quality of Life Associated With the Use of Olapatadine 0.2% for the Treatment of Allergic Conjunctivitis Completed NCT01159769 Phase 4 Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
29 A Placebo Controlled Comparison of Topical Zirgan Versus Genteal Gel for the Treatment of Adenovirus Conjunctivitis Completed NCT01533480 Phase 4 Zirgan;genteal gel
30 A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis Completed NCT01470118 Phase 4 alcaftadine 0.25% ophthalmic solution;olopatadine 0.2% ophthalmic solution;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
31 A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis Completed NCT01732757 Phase 4 Alcaftadine 0.25%;Olopatadine 0.2%;dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
32 Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
33 A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis Completed NCT00464438 Phase 4 gatifloxacin;moxifloxacin 0.5% eye drops
34 Study of Two Marketed Ocular Anti-Allergy Medications in Subjects With Allergic Conjunctivitis Completed NCT00534794 Phase 4 Elestat;Pataday
35 Efficacy Investigation Study of Olopatadine Hydrochloride Ophthalmic Solution Using OHIO Chamber in Patients With Seasonal Allergic Rhinitis (SAR) Completed NCT00818805 Phase 4 Olopatadine 0.1%;Tranilast 0.5%;Placebo (Olopatadine);Placebo (Tranilast)
36 Patient Perception Study for AL-4943A Completed NCT01294969 Phase 4 AL-4943A
37 Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Pediatric Patients Completed NCT01109485 Phase 4 Olopatadine hydrochloride ophthalmic solution 0.1%
38 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT00689078 Phase 4 Prednisolone Acetate 1%;Prednisolone Acetate 0.12%;Loteprednol Etabonate 0.2%;Placebo
39 Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model Completed NCT01534195 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
40 Assessment of Alcon's Ocular Image Quantification System Completed NCT01282138 Phase 4 Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)
41 Mast-Cell Stabilizing Effects of Olopatadine Completed NCT00389025 Phase 4 Olopatadine (generic name)
42 A Study of the Effects of Desloratadine on Conjunctival Allergen Challenge-induced Ocular Signs and Symptoms (Study P04209) Completed NCT00311844 Phase 4 desloratadine
43 Study of the Effect of Fluticasone Furoate Nasal Spray on Spring Allergy Eye Symptoms Completed NCT00891436 Phase 4 Fluticasone furoate nasal spray;Placebo nasal spray
44 Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006) Completed NCT02256553 Phase 4 Rescue Medication
45 Safety and Efficacy of Zylet vs Lotemax, Tobramycin and Vehicle in Pediatric Blepharoconjunctivitis Completed NCT00705159 Phase 4 loteprednol etabonate and tobramycin;loteprednol etabonate;Tobramycin;Vehicle of Zylet
46 A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy Completed NCT02308501 Phase 4 Lastacaft ®;Tears Naturale ®
47 Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model Completed NCT01730872 Phase 4 Prednisolone Sodium Phosphate Ophthalmic Solution 1%;Tears Naturale II Ophthalmic Solution
48 Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine Completed NCT01179412 Phase 4 2% povidone-iodine;2% povidone-iodine
49 An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo Completed NCT01439815 Phase 4 Fluticasone Propionate Nasal Spray;Saline Nasal Spray
50 Topical Cyclosporine for Vernal Keratoconjunctivitis (VKC) in Rwanda Completed NCT01211327 Phase 4 Cyclosporine A;Dexamethasone

Search NIH Clinical Center for Conjunctivitis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: conjunctivitis

Sources

Genetic Tests for Conjunctivitis

About this section

Genetic tests related to Conjunctivitis:

# Genetic test Affiliating Genes
1 Conjunctivitis 30
Sources

Anatomical Context for Conjunctivitis

About this section

MalaCards organs/tissues related to Conjunctivitis:

42
Eye, Testes, Skin, T Cells, Thyroid, Salivary Gland, B Cells
Sources

Publications for Conjunctivitis

About this section

Articles related to Conjunctivitis:

(show top 50) (show all 3042)
# Title Authors Year
1
Re-emergence of a coxsackievirus A24 variant causing acute hemorrhagic conjunctivitis in Brazil from 2017 to 2018. ( 30725183 )
2019
2
Diagnosing and managing allergic conjunctivitis in childhood: the allergist's perspective. ( 30742722 )
2019
3
Low Expression of IL-10 in Circulating Bregs and Inverted IL-10/TNF-α Ratio in Tears of Patients with Perennial Allergic Conjunctivitis: A Preliminary Study. ( 30818819 )
2019
4
Bicanalicular Silicone Intubation for the Management of Punctal Stenosis and Obstruction in Patients With Allergic Conjunctivitis. ( 30844917 )
2019
5
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects. ( 30858690 )
2019
6
Corrigendum to "Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression" [EBioMedicine 28 (2018) 274-286]. ( 30885727 )
2019
7
An association analysis to identify genetic variants linked to asthma and rhino-conjunctivitis in a cohort of Sicilian children. ( 30646946 )
2019
8
Correction to: Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.3% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial, by Baiza-Durán, L., Olvera-Montaño, O., Mercado-Sesma, A.R., and Oregon-Miranda, A.A. J Ocul Pharmacol Ther 2018;34(3):250-255. DOI: 10.1089/jop.2017.0056. ( 30699060 )
2019
9
Adult conjunctivitis secondary to dual infection with Chlamydia trachomatis and Neisseria gonorrhoeae - A case report. ( 30505977 )
2019
10
Chronic Conjunctivitis From a Retained Contact Lens. ( 30724838 )
2019
11
Optimizing Accessibility of a Hand-wash Gel to Infant's Cradle: Effect on Neonatal Conjunctivitis. ( 29570175 )
2019
12
Ligneous conjunctivitis in a Dandy-Walker syndrome: A rare case report. ( 30574926 )
2019
13
Asymptomatic Follicular Conjunctivitis in an Elderly Man. ( 30653223 )
2019
14
Evaluation of a Silver-amplified Immunochromatography Kit for Adenoviral Conjunctivitis. ( 30659635 )
2019
15
Retraction: Treatment of Ligneous Conjunctivitis Using Topical Plasminogen Therapy in An 8-Week-Old Female Infant. ( 30673103 )
2019
16
Letter regarding "Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment". ( 30717876 )
2019
17
Development of conjunctivitis with a conjunctival proliferative lesion in a patient treated with dupilumab for atopic dermatitis. ( 30718036 )
2019
18
Conjunctivitis in dupilumab clinical trials. ( 30851191 )
2019
19
The change in the prevalence of wheeze, eczema and rhino-conjunctivitis among Japanese children: findings from 3 nation-wide cross-sectional surveys between 2005 and 2015. ( 30866051 )
2019
20
Management of dupilumab-associated conjunctivitis in atopic dermatitis. ( 30873757 )
2019
21
Pseudomembranous conjunctivitis: unveil the curtain. ( 30878958 )
2019
22
Infective conjunctivitis progressing to posterior scleritis. ( 30912241 )
2019
23
Could conjunctivitis in dupilumab treated atopic dermatitis patients be caused by colonization with Demodex and increased IL-17 levels? Reply from authors. ( 29336016 )
2018
24
Conjunctivitis, mucosal erosions, and moist cutaneous plaques. ( 29349113 )
2018
25
Incidence, clinical features and diagnosis of cicatrising conjunctivitis in Australia and New Zealand. ( 29921954 )
2018
26
Seasonal and Temporal Trends in Childhood Conjunctivitis in Burkina Faso. ( 29761759 )
2018
27
Pseudoallergic conjunctivitis induced by tamsulosin, a selective alpha-1 adrenergic receptor antagonist. ( 29705339 )
2018
28
Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis. ( 29787732 )
2018
29
Coxsackievirus A24 Variant Associated with Acute Haemorrhagic Conjunctivitis Cases, French Guiana, 2017. ( 29898445 )
2018
30
Bacterial conjunctivitis in childhood: etiology, clinical manifestations, diagnosis, and management. ( 29380707 )
2018
31
Dacryoadenitis due to gonococcal conjunctivitis complicated by corneal perforation. ( 29565715 )
2018
32
Treatment with galectin-1 eye drops regulates mast cell degranulation and attenuates the severity of conjunctivitis. ( 29859836 )
2018
33
Contact lenses with dual drug delivery for the treatment of bacterial conjunctivitis. ( 29960036 )
2018
34
Variation in the TEK gene is not associated with asthma but with allergic conjunctivitis. ( 29667338 )
2018
35
Ocular Munchhausen's syndrome: Self-inflicted conjunctivitis. ( 29903587 )
2018
36
A novel herpesvirus associated with chronic superficial keratitis and proliferative conjunctivitis in a great horned owl (Bubo virginianus). ( 29656541 )
2018
37
Bepotastine besilate ophthalmic solution 1.5% for alleviating nasal symptoms in patients with allergic conjunctivitis. ( 29615844 )
2018
38
Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study. ( 29543548 )
2018
39
Conjunctivitis Occurring in Atopic Dermatitis Patients Treated with Dupilumab - Clinical Characteristics and Treatment. ( 29432961 )
2018
40
Allergic conjunctivitis: current concepts on pathogenesis and management. ( 29552874 )
2018
41
Allergic Conjunctivitis-induced Retinal Inflammation Promotes Myopia Progression. ( 29398596 )
2018
42
A Biodegradable, Sustained-Released, Tacrolimus Microfilm Drug Delivery System for the Management of Allergic Conjunctivitis in a Mouse Model. ( 29392313 )
2018
43
Tear osteopontin level and its relationship with local Th1/Th2/Th17/Treg cytokines in children with allergic conjunctivitis. ( 29279263 )
2018
44
Aetiology of neonatal conjunctivitis evaluated in a population-based setting. ( 29345007 )
2018
45
Rapamycin attenuates Th2-driven experimental allergic conjunctivitis. ( 29432811 )
2018
46
Sublingual immunotherapy for pediatric allergic conjunctivitis: a meta-analysis of randomized controlled trials. ( 29782067 )
2018
47
Re: Keen etA al.: Treatment of acute conjunctivitis in the United States and evidence of antibiotic overuse: isolated issue or a systematic problem? (Ophthalmology. 2017;124:1096-1098). ( 29935672 )
2018
48
Antibodies to Conserved Surface Polysaccharides Protect Mice Against Bacterial Conjunctivitis. ( 29847658 )
2018
49
Topical Olopatadine Hydrochloride versus Ketotifen Fumarate for Allergic Conjunctivitis. ( 29719638 )
2018
50
Spatial analysis between particulate matter and emergency room visits for conjunctivitis and keratitis. ( 29942521 )
2018
Sources

Variations for Conjunctivitis

About this section
Sources

Expression for Conjunctivitis

About this section
Search GEO for disease gene expression data for Conjunctivitis.
Sources

Pathways for Conjunctivitis

About this section

Pathways related to Conjunctivitis according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.03 CCL11 CXCL8 EPX ICAM1 IFNG IL13
2
PEDF Induced Signaling 65
Show member pathways
 13.65 CCL11 CXCL8 IFNG IL13 IL2 IL4
3
TGF-Beta Pathway 65
Show member pathways
 13.55 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
4
Cytokine Signaling in Immune system 67
Show member pathways
 13.41 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
5
Akt Signaling 65
Show member pathways
 13.39 CCL11 CXCL8 IL13 IL2 IL4 IL5
6
PAK Pathway 65
Show member pathways
 13.3 CCL11 CXCL8 IL13 IL2 IL4 IL5
7
Pathways in cancer 38
12.9 CXCL8 IFNG IL13 IL2 IL4 IL5
8
Th17 cell differentiation 38
Show member pathways
 12.67 FOXP3 IFNG IL13 IL2 IL4 IL5
9
Influenza A 38
Show member pathways
 12.59 CXCL8 ICAM1 IFNG IL13 IL2 IL4
10
Immune response IL-23 signaling pathway 23
Show member pathways
 12.56 IFNG IL2 IL6 PLG
11
Immune response Fc epsilon RI pathway 23
Show member pathways
 12.56 IL13 IL4 IL5 MS4A2
12
NF-kappaB Signaling 4
12.54 FOXP3 IFNG IL2 IL4
13
Immune response Role of DAP12 receptors in NK cells 23
Show member pathways
 12.49 ICAM1 IFNG IL2 IL4
14
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.48 IFNG IL13 IL2 IL4 IL5 IL6
15
T cell receptor signaling pathway 38
Show member pathways
 12.47 IFNG IL2 IL4 IL5 IL6
16
Selenium Micronutrient Network 1
Show member pathways
 12.42 ICAM1 IFNG IL2 IL4 IL6 PLG
17
IL-17 Family Signaling Pathways 66
Show member pathways
 12.4 CCL11 CXCL8 IFNG IL13 IL4 IL5
18
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.33 CXCL8 IFNG IL13 IL2 IL4 IL5
19
Bacterial infections in CF airways 23
Show member pathways
 12.27 CCL11 CXCL8 IFNG IL4 IL6
20
Allograft rejection 1 38
Show member pathways
 12.18 CCL11 CXCL8 EPX FOXP3 ICAM1 IFNG
21
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 12.12 IFNG IL13 IL4 IL6 PLG
22
Spinal Cord Injury 1
12.1 CXCL8 ICAM1 IFNG IL2 IL4 IL6
23
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
12.08 IFNG IL2 IL4 IL5 IL6
24
Interleukin-4 and 13 signaling 67
12.07 CCL11 CXCL8 ICAM1 IL13 IL4 IL6
25
MAPK Pathway 73
Show member pathways
 12 IL13 IL2 IL5
26
Immune response IFN gamma signaling pathway 23
Show member pathways
 11.99 CCL11 CXCL8 ICAM1 IFNG IL13 IL2
27
IL12-mediated signaling events 1
Show member pathways
 11.95 IFNG IL2 IL4
28
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.93 CXCL8 FOXP3 ICAM1 IL6
29
Senescence and Autophagy in Cancer 1
11.92 CXCL8 IFNG IL6
30
Rheumatoid arthritis 38
11.91 CXCL8 ICAM1 IFNG IL6
31
Innate Lymphoid Cell Differentiation Pathways 66
11.9 IFNG IL13 IL2 IL4 IL5
32
AGE-RAGE signaling pathway in diabetic complications 38
11.89 CXCL8 ICAM1 IL6
33
Hematopoietic cell lineage 38
11.88 IL4 IL5 IL6
34
Amoebiasis 38
11.87 CXCL8 IFNG IL6
35
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.84 CXCL8 FOXP3 IFNG IL2 IL4 IL5
36
Salmonella infection (KEGG) 38
11.82 CXCL8 IFNG IL6
37
Pertussis 38
11.76 CXCL8 IL6 NLRP3
38
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.76 CXCL8 ICAM1 IFNG IL2 IL6
39
Dendritic Cells Developmental Lineage Pathway 66
11.75 IFNG IL2 IL6
40
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.73 CCL11 IFNG IL13 IL2 IL4 IL6
41
IL2 signaling events mediated by PI3K 1
Show member pathways
 11.7 FOXP3 IL2 IL4
42
IL4-mediated signaling events 1
11.67 CCL11 IL4 IL5
43
Interleukin-10 signaling 67
11.65 CXCL8 ICAM1 IL13 IL4 IL6
44
Lung fibrosis 1
11.64 CCL11 CXCL8 IL13 IL4 IL5 IL6
45
Malaria 38
11.63 CXCL8 ICAM1 IFNG IL6
46
ATF-2 transcription factor network 1
11.61 CXCL8 IFNG IL6
47
Photodynamic therapy-induced AP-1 survival signaling. 1
11.57 IFNG IL2 IL6
48
amb2 Integrin signaling 1
11.54 ICAM1 IL6 PLG
49
Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway 1
11.53 CCL11 CXCL8 IL6
50
Immune response_Role of integrins in NK cells cytotoxicity 23
11.5 CXCL8 ICAM1 IFNG
Sources

GO Terms for Conjunctivitis

About this section

Cellular components related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.77 CCL11 CXCL8 EPX IFNG IL13 IL2
2 extracellular space GO:0005615 9.44 CCL11 CXCL8 EPX ICAM1 IFNG IL13

Biological processes related to Conjunctivitis according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.93 FOXP3 IFNG IL13 IL4 IL6
2 regulation of signaling receptor activity GO:0010469 9.86 CCL11 CXCL8 IFNG IL13 IL2 IL4
3 response to ethanol GO:0045471 9.82 ICAM1 IL13 IL2
4 response to virus GO:0009615 9.81 CCL11 FOXP3 IFNG
5 negative regulation of inflammatory response GO:0050728 9.81 FOXP3 IL2 NLRP3
6 cellular response to lipopolysaccharide GO:0071222 9.81 CXCL8 ICAM1 IL6 NLRP3
7 defense response to Gram-positive bacterium GO:0050830 9.8 IL6 NLRP3 RNASE3
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.78 ICAM1 IL5 IL6
9 cellular response to interleukin-1 GO:0071347 9.77 CCL11 CXCL8 ICAM1
10 inflammatory response GO:0006954 9.76 CCL11 CXCL8 HRH1 IL13 IL5 IL6
11 positive regulation of T cell proliferation GO:0042102 9.74 IL2 IL4 IL6
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 IFNG IL13 IL2 IL4 IL6
13 positive regulation of B cell proliferation GO:0030890 9.67 IL13 IL2 IL4 IL5
14 negative regulation of endothelial cell apoptotic process GO:2000352 9.65 ICAM1 IL13 IL4
15 negative regulation of interleukin-10 production GO:0032693 9.63 EPX FOXP3
16 positive regulation of interleukin-4 production GO:0032753 9.63 EPX FOXP3 NLRP3
17 negative regulation of interleukin-17 production GO:0032700 9.62 FOXP3 IFNG
18 positive regulation of regulatory T cell differentiation GO:0045591 9.61 FOXP3 IL2
19 regulation of regulatory T cell differentiation GO:0045589 9.61 FOXP3 IFNG IL2
20 immune response GO:0006955 9.61 CCL11 CXCL8 IFNG IL13 IL2 IL4
21 positive regulation of isotype switching to IgG isotypes GO:0048304 9.59 IL2 IL4
22 positive regulation of interleukin-13 production GO:0032736 9.58 IL4 NLRP3
23 negative regulation of T-helper 17 cell differentiation GO:2000320 9.58 FOXP3 IL2
24 positive regulation of immunoglobulin secretion GO:0051024 9.58 IL2 IL5 IL6
25 negative regulation of lymphocyte proliferation GO:0050672 9.56 FOXP3 IL2
26 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.55 IL6 NLRP3
27 negative regulation of interleukin-5 production GO:0032714 9.52 EPX FOXP3
28 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL13 IL4
29 cytokine-mediated signaling pathway GO:0019221 9.23 CCL11 CXCL8 ICAM1 IL13 IL2 IL4

Molecular functions related to Conjunctivitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.26 IL2 IL4 IL5 IL6
2 cytokine activity GO:0005125 9.23 CCL11 CXCL8 IFNG IL13 IL2 IL4
Sources

Sources for Conjunctivitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....